Compare Dicks Sporting Goods Inc (DKS) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dicks Sporting Goods Inc vs Gilead Sciences, Inc. — how do they compare? Dicks Sporting Goods Inc trades at $206.29 (market cap $19.16B), while Gilead Sciences, Inc. trades at $135 (market cap $164.99B). The key difference: Gilead Sciences, Inc. is far larger — about 8.6× Dicks Sporting Goods Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.47%). Which is the better fit depends on your goals.
| DKS | GILD | |
|---|---|---|
Market Cap | $19.16B | $164.99B |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $155.80 |
52-Week Low | $187.78 | $110.56 |
Enterprise Value | $25.95B | $188.06B |
Dividend Yield | 2.34% | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DICK'S Sporting Goods (DKS) trades at $208.84, up 5.15% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows neutral technical signals with support at $201 and resistance at $213. Fundamentally, the company maintains solid profitability with 20.9% ROE and 4.71% net margin, though cash flow trends show modest net outflows. Recent news highlights analyst upgrades and the upcoming Q2 earnings call on August 25th.
The investment outlook remains positive with 59% analyst buy ratings and a $263.22 consensus target representing 26% upside. Key risks include potential fiduciary duty investigations and competitive pressures in sporting goods retail. The company's consistent earnings beats and expanding women's sports investments provide catalysts, though investors should monitor cash flow sustainability and market volatility.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
